We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.
|Recent Press Releases||More >>|
|March 28, 2018 – 8:31 a.m.|
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Xenon Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|